Who is the CEO of Jazz Pharmaceuticals?

Who is the CEO of Jazz Pharmaceuticals?

Bruce C Cozadd (Apr 2009–)Jazz Pharmaceuticals / CEO

Who Owns Jazz Pharmaceutical?

Bruce C. Cozadd
Jazz Pharmaceuticals

Type Public company
Key people Bruce C. Cozadd (Chairman & CEO)
Products Pharmaceutical drugs
Brands Xyrem Erwinaze Defitelio FazaClo FazaClo HD Luvox CR Prialt Vyxeos
Revenue US$1.618 billion (2017)

Is Jazz Pharmaceuticals a good company?

Is Jazz Pharmaceuticals a good company to work for? Jazz Pharmaceuticals has an overall rating of 3.8 out of 5, based on over 206 reviews left anonymously by employees. 75% of employees would recommend working at Jazz Pharmaceuticals to a friend and 73% have a positive outlook for the business.

Did Jazz Pharma buy pharma?

DUBLIN , May 5, 2021 /PRNewswire/ — Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”), a leader in the science, development and commercialization of cannabinoid-based prescription medicines.

Who is Seamus Mulligan?

Seamus Mulligan, the founder of Adapt Pharma, serves as the Chairman and Chief Executive Officer. Previously Seamus founded and served as Chairman and Chief Executive Officer of Azur Pharma, which merged with Jazz Pharmaceuticals plc in 2012. Seamus continues to serve as a Director of Jazz Pharmaceuticals.

Who founded Jazz Pharmaceuticals?

Bruce Cozadd
Rob Wright, chief editor, Life Science Leader (left) with Bruce Cozadd (right), cofounder, chairman, and CEO of Jazz Pharmaceuticals (NASDAQ: JAZZ), Philadelphia, PA, April 7, 2015.

Where Is Jazz Pharma based?

Dublin, Ireland
Our corporate headquarters are located in Dublin, Ireland. In the North America, we have offices in Palo Alto and Carlsbad, California; Philadelphia, Pennsylvania; Vancouver, British Columbia; and Mississauga, Ontario.

What is Jazz Pharma known for?

Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.

Where is Jazz Pharmaceuticals located?

Should I invest in Jazz Pharmaceuticals?

Jazz Pharmaceuticals PLC – Hold Its Value Score of A indicates it would be a good pick for value investors. The financial health and growth prospects of JAZZ, demonstrate its potential to outperform the market. It currently has a Growth Score of A.

What happened to GW Pharma?

Jazz Pharmaceuticals (NASDAQ:JAZZ) has officially closed its $7.2B acquisition of GW Pharmaceuticals plc (NASDAQ:GWPH). GW shareholders gave the thumbs up to the deal last month. With the acquisition, Jazz gains access to GW’s cannabinoid portfolio, including Epidiolex, which raked in $510.5M in sales in 2020.

Where is Seamus Mulligan from?

Seamus Mulligan (58), a serial pharmaceuticals entrepreneur from Waterford had a hugely successful year in 2018.

How many people work at Jazz Pharmaceuticals?

Together, we are more than 3,100 experts, analysts, specialists, advocates, scientists and professionals all with diverse backgrounds and perspectives. Working together, we are proud to support patients, innovate and bring new medicines to market.

Where Did Jazz Pharmaceuticals come from?

The company was founded on January 18, 2012 and is headquartered in Dublin, Ireland.

Is JAZZ a buy or sell?

Jazz Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.

Where is Epidiolex manufactured?

Manufactured by U.K.-based GW Pharmaceuticals, the cannabis drug is derived from a plant that has been bred to have a high cannabidiol, or CBD, content.

What kind of company is Jazz Pharmaceuticals plc?

About Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc(NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options.

What are Jazz Pharmaceuticals’price targets for the next 12 months?

13 equities research analysts have issued 12 month price targets for Jazz Pharmaceuticals’ stock. Their forecasts range from $174.00 to $250.00. On average, they anticipate Jazz Pharmaceuticals’ stock price to reach $205.54 in the next twelve months. This suggests a possible upside of 34.3% from the stock’s current price.

How much of Jazz Pharmaceuticals stock are insiders buying or selling?

In the past three months, Jazz Pharmaceuticals insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $887,174.00 in company stock. Only 4.30% of the stock of Jazz Pharmaceuticals is held by insiders. 91.95% of the stock of Jazz Pharmaceuticals is held by institutions.

Does Jazz Pharmaceuticals own Vyxeos?

As a result, Jazz obtained the rights to breakthrough therapy Vyxeos (liposomal daunorubicin and cytarabine) for treatment of acute myeloid leukemia. In August 2019, the company announced it would acquire Cavion Inc. for up to ~$310 million.